Purple Biotech (PPBT) files 6-K on IM1240 manufacturing milestone

Q: What did Purple Biotech (PPBT) file?

The company furnished a Form 6-K reporting it issued a press release on an IM1240 manufacturing milestone.

Q: What is the subject of the press release in PPBT’s 6-K?

A manufacturing milestone for IM1240, a tri-specific antibody from the CAPTN-3 platform.

Q: When was the Purple Biotech press release issued?

The press release is dated October 29, 2025.

Q: Where can I find the press release within the 6-K?

It is attached as Exhibit 99.1.

Accepted by SEC EDGAR 10/29/2025 - 07:33 AM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

Purple Biotech Ltd. furnished a Form 6-K noting it issued a press release titled “Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform.” The press release is included as Exhibit 99.1 and is dated October 29, 2025.

The filing is administrative and points readers to the attached press release for details on the IM1240 manufacturing milestone from the CAPTN-3 platform.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Purple Biotech (PPBT) file?

The company furnished a Form 6-K reporting it issued a press release on an IM1240 manufacturing milestone.

What is the subject of the press release in PPBT’s 6-K?

A manufacturing milestone for IM1240, a tri-specific antibody from the CAPTN-3 platform.

When was the Purple Biotech press release issued?

The press release is dated October 29, 2025.

Where can I find the press release within the 6-K?

It is attached as Exhibit 99.1.

Does the 6-K include financial results for PPBT?

No. It furnishes a press release regarding a manufacturing milestone for IM1240.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of October 2025

Commission File Number: 001-37643

PURPLE BIOTECH LTD.

(Translation of registrant’s name into English)

4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Purple Biotech

On October 29 , 2025, Purple Biotech Ltd. (the “Company” or the “Registrant”) issued a press release “Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform”, which is attached hereto as Exhibit 99.1.

Exhibit
99.1		Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

October 29, 2025	PURPLE BIOTECH LTD.

	By:	/s/ Gil Efron
		Gil Efron
		Chief Executive Officer

Source: View Original Filing on SEC EDGAR